Locations:

Psychogenic Nonepileptic Seizures: What Neurologists Need to Know (Podcast)

Two experts share diagnostic and treatment essentials on a sensitive, poorly understood condition

About three of every 10 patients evaluated in Cleveland Clinic’s epilepsy monitoring unit are diagnosed with psychogenic nonepileptic seizures (PNES). Despite being so prevalent, the condition is poorly understood by some providers and the diagnosis is difficult for some patients to accept. Yet effective treatment is possible with the right collaborative expertise.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In the latest episode of Cleveland Clinic’s peer-to-peer Neuro Pathways podcast, neurologist Jocelyn Bautista, MD, and clinical psychologist Becky Bikat Tilahun, PhD, share their PNES expertise in an effort to bring some clarity to this complex condition. The ground they cover includes:

  • What causes PNES and how it differs from epilepsy
  • When and why clinicians might suspect PNES in a patient with seizures
  • What the evaluation for PNES involves
  • Considerations for presenting the PNES diagnosis to a patient
  • What’s necessary for effective treatment of PNES

Click the player below to listen to the 19-minute podcast now, or read on below for a short edited excerpt of the discussion. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

Excerpt from the podcast

Dr. Alex Rae-Grant (podcast host): I expect that presenting a diagnosis of PNES to a patient needs to be handled somewhat delicately. How do you approach that in your practice?

Dr. Bautista: Typically we deliver this diagnosis in the epilepsy monitoring unit, after we’ve recorded the episodes in question. Every physician has a different style and different phrases or analogies we might use. But the main message we want to convey is that these are real symptoms and that this is a condition that we see quite a lot. As you mentioned earlier, 30% of our patients in the monitoring unit are diagnosed with PNES. So this is certainly a condition that we’ve seen and treated and it can get better.

It’s important to try to make the connection between emotions and psychological distress and how that can be converted to physical symptoms such as nonepileptic seizures. And it’s incredibly important to take your time and to deliver the diagnosis with empathy for what the patient has been through and what this has done to their life, and to be as patient as possible and constantly checking to confirm their understanding after you’ve explained something.

Advertisement

So it does take time, but it’s crucial. Delivering the diagnosis effectively can actually be therapeutic in the short term. Whereas if it’s not delivered effectively, the patient can go away angry and the seizures will likely get worse.

Advertisement

Related Articles

mosquito on human skin

Rare New Neuroinvasive Threat Identified for Patients on B Cell-Depleting Therapy

Milestone case report expands understanding of infectious risks for those on immunomodulatory therapies

Head shots of Susan Linder and Karen Green
November 3, 2026/Neurosciences/Podcast

Connecting Neuro Rehab Research and Clinical Care (Podcast)

Advanced technologies are changing expectations about what’s possible

illustration of street entrance to a hospital emergency area

Architecture as a Therapeutic Tool: Acute Stroke Care in Our New Neurological Building

A rare opportunity to design for speed, care coordination, recovery and continuous monitoring

Doctor and hospital tech standing next to an older patient in a hospital bed

Inpatient Program Reduced Medication Errors in Patients With Parkinson’s Disease

Multidisciplinary, proactive approach also improved discharge outcomes

floating CAR T cell against background of other cells

Zola-Cel CAR T-Cell Therapy Shows Promising Initial Results in Multiple Sclerosis

Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26

woman in lab holding two vials filled with liquids
October 19, 2026/Neurosciences/Brain Health

CSF and Plasma Analytes Reveal Early Clues to Alzheimer’s Development

Inflammatory protein eotaxin-1 may be a marker of future cognitive decline

headshots of Drs. Lilly and Barron

Early Mobilization in Neuro Intensive Care (Podcast)

Therapists and physicians collaborate to get medically stable patients moving

23-NEU-3627359-CQD-Hero-650×450

6 Things to Know About the New Home of Our Neurological Institute

Designed for digitization, distance health, discovery and more

Ad